Ergothioneine,
does it really help with Antioxidant effects and healthy aging?
research showsErgothioneine is absorbed and retained in humans and was generally well tolerated in short-term and one-year supplementation trials. However, most oxidative-damage and inflammatory biomarkers in a 45-person trial were not significant, and the primary memory endpoint in a 147-person trial of older adults did not differ from placebo. Signals in learning and a neuronal-injury biomarker from a 19-person mild-cognitive-impairment pilot were too small to establish the claim, so antioxidant effects and healthy aging are rated C.
ads claimMarketing combines a dietary antioxidant, a longevity nutrient, and protection from brain aging into one effect. Human data mainly concern blood concentrations, oxidative-damage biomarkers, short-term cognitive tests, and a neuronal-injury biomarker, not healthspan, mortality, or lifespan.
Useful facts when choosing a product
- Human trials used 5-25 mg/day or 25 mg three times weekly.
- The 45-person short trial found dose-dependent increases in blood ergothioneine.
- The primary composite-memory endpoint in the 147-person trial was not significant versus placebo.
- No supplementation trial directly measured healthspan or lifespan extension.
Chamgap Semantic Classification Code
Candidate index · review held
S.ergothioneine.UNK.antioxidant-effects-and-healthy-aging.assess.placeboSupplements and nutraceuticals > Ergothioneine > Unknown > Antioxidant effects and healthy aging > Association or change assessment > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The Cheah 2017 trial assigned 45 healthy men to placebo, 5 mg, or 25 mg for seven days and confirmed blood accumulation, but most oxidative-damage and CRP changes were not significant. The Yau 2024 pilot enrolled 19 people with mild cognitive impairment, of whom 14 completed one year of 25 mg three times weekly, and reported signals in a learning test and stabilization of neurofilament light. The Zajac 2025 trial gave 10 mg or 25 mg for 16 weeks to 147 older adults with subjective memory complaints; the primary composite-memory endpoint did not differ from placebo, while selected subjective memory and sleep outcomes were positive.
Why this is classified as C (40)
Randomized human trials and bioavailability data mean the evidence is not ungradable, but mostly negative antioxidant biomarkers, a negative primary endpoint in 147 participants, and reliance on a small pilot and exploratory outcomes place it at the bottom of C with 40 points.
Counterpoint. Signals in learning and a neuronal-injury biomarker were observed in people with mild cognitive impairment, so this judgment does not state that every human effect is absent.
Rejudgment record. New judgment — Human RCTs exist, but most oxidative-damage biomarkers were nonsignificant, the primary memory endpoint in 147 participants was negative, and no direct healthspan endpoint exists
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Antioxidant biomarkers | C | A 45-person trial showed downward trends, but most changes were nonsignificant |
| Healthspan and lifespan extension | ? | No trial directly assessed human healthspan, mortality, or lifespan |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Cheah IK et al. 2017 | Randomized double-blind placebo-controlled pharmacokinetic and biomarker trial | 45 | Unknown | Blood concentrations, oxidative damage, and CRP | Blood accumulation was dose-dependent, but most oxidative-damage and inflammatory biomarker changes were nonsignificant. | Key |
| Yau YF et al. 2024 | Double-blind randomized placebo-controlled pilot | 14 | Singapore academic research | Cognitive tests, neurofilament light, and safety | Learning-test and neurofilament-light stabilization signals were reported, but only 14 participants completed the trial. | Supportive |
| Zajac IT et al. 2025 | Randomized double-blind placebo-controlled dose-ranging trial | 147 | Phyto Tech/Blue California | Composite memory, cognition, sleep, and telomere length at 16 weeks | The primary composite-memory outcome did not differ from placebo; only selected subjective and exploratory outcomes were positive. | Key |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-11).
Final verification and publication gate: Codex · Evidence date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Ergothioneine x Antioxidant effects and healthy aging — Evidence Grade C·40. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/ergothioneine-antioxidant-healthy-aging/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.